Taysha Gene Therapies Shares Outstanding 2020-2024 | TSHA
Taysha Gene Therapies shares outstanding from 2020 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Taysha Gene Therapies Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
116 |
| 2022 |
44 |
| 2021 |
38 |
| 2020 |
18 |
| 2019 |
|
Taysha Gene Therapies Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-06-30 |
233 |
| 2024-03-31 |
231 |
| 2023-12-31 |
116 |
| 2023-09-30 |
126 |
| 2023-06-30 |
64 |
| 2023-03-31 |
63 |
| 2022-12-31 |
44 |
| 2022-09-30 |
41 |
| 2022-06-30 |
40 |
| 2022-03-31 |
38 |
| 2021-12-31 |
38 |
| 2021-09-30 |
38 |
| 2021-06-30 |
37 |
| 2021-03-31 |
37 |
| 2020-12-31 |
18 |
| 2020-09-30 |
12 |
| 2020-06-30 |
11 |
| 2020-03-31 |
11 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.314B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
